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Medicines are health technologies that can translate into tangible benefits for numerous acute as well as
chronic health conditions. A nation’s pharmaceutical sector needs to be appropriately structured and
managed in order to ensure a safe, effective and quality supply of medicines to society. The process of
medicines management involves the sequential management of five critical activity areas; namely; registration,
selection, procurement, distribution and use. Formalized and standardized management of all five critical
activity areas positively influences the availability, quality and affordability of medicines and ultimately
increases the reliability and quality of the national healthcare system.
Aim: The aim of this review is to examine the current structure and operation of medicines management (i.e.
the pharmaceutical sector) in Libya.
Conclusion: In the Libyan healthcare system all five critical activity areas are compromised. Restructuring of
the pharmaceutical sector in Libya is required in order to provide and sustain sound pharmaceutical services
for Libyan society and improve the national public health outcomes.
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M
edicines are health commodities that can
translate into tangible benefits for numerous
acute as well as chronic health conditions (1).
The pharmaceutical sector of any nation is responsible
for providing society with medicines and other pharma-
ceutical services. Flaws in the structure and management
of the pharmaceutical sector can limit the population’s
access to quality pharmaceuticals, thereby depriving
society of the health gains associated with these life-
saving commodities.
The pharmaceutical sector is a multifaceted and
technically complex arena that requires highly skilled
personnel and a standardized operational infrastructure.
Government should therefore hold the task of manage-
ment of the pharmaceutical sector in order to ensure that
it is institutionally sound and operates efficiently and in
harmony with other healthcare sectors (2). Governments
need to ensure that medicines are appropriately manu-
factured, supplied, and used (3, 4).
For the pharmaceutical sector to operate safely and
efficiently the sequential operation of five primary areas
of activity are required (3, 5): medicines registration,
medicines selection, medicines procurement, medicines
distribution, and medicines use (see Fig. 1).
Libya is an upper middle income North African nation
that strives for high standard healthcare services (6).
Nevertheless, according to the World Health Organiza-
tion (WHO) ‘Inappropriate management of drug supply
and distribution’ is a major constraint facing health
development in Libya (6). Evidence from local
studies (7, 8) and the WHO (6) indicate that medicines
management in Libya requires reconsideration. This
paper will provide an overview in relation to each of
the five critical areas of activity in the pharmaceutical
sector and highlight processes that could be improved.
Medicines registration
Medicines registration is a critical regulatory function of
the government (Ministry of Health) that should ensure
that all medicines that are available within the nation’s
health system are safe, effective, and of good quality (2).
The process of medicines registration evaluates the
efficacy of a given medicine for a specific clinical
indication as well as its safety and adverse effect profile
(9). It is important to stress that the registration process
should approve a particular product (dosage form and
dosage strength) from a specific manufacturer only,
as opposed to the singular generic active ingredient.
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regulate the presentation and use of all medicinal
products (e.g. labeling, storage conditions, marketing,
warnings, and prescription requirements) (2, 5). Even
though one generic medicine may be available nationally
as many different products (i.e. dosage forms and
strengths) from a variety of manufacturers, each of these
individual products should undergo individual review
and registration by the registering authorities (3).
It is also critical to stress that medicines registration
should not be limited to the approval of new medicines,
but should also include the periodical review of existing
products on the national market (2).
Public health relevance of robust medicines
registration
Weak, inefficient, or hasty non-systematic medicine
registration systems increase the potential for infiltration
of the national healthcare system with poor quality,
irrational, substandard, or counterfeit medicines (1014).
The public health consequences of substandard or
counterfeit medicines can undermine the whole health-
care process and waste national healthcare resources (14).
Substandard medicines impose a silent threat to health-
care systems that can lead to morbidity or, at worst,
mortality. Antimicrobial medicines are of particular
concern. Substandard quantities or unwanted inclusion
of other antimicrobial medicines or contaminants in a
medicinal product could cause treatment failure, have
safety implications, or aggravate problems of antimicro-
bial resistance (12).
Medicine registration in Libya
Despite the fact that a medicines regulatory authority
should be a vital component of any national health
system, the WHO estimates that only one in six nations
worldwide have fully functioning medicine registration
systems; most of which are located in high-resourced
nations (15). In developing nations, many barriers under-
mine the availability and/or the efficiency of medicine
registration systems (13). According to Caudron et al.
these barriers include a limited understanding of the
significance of medicines registration as a key and critical
regulatory step by national decision makers, the lack of
essential infrastructure such as quality assurance labora-
tories, and appropriately trained human resources. These
barriers have rendered registration of medicines in
developing countries a process that is mainly based on
document review and estimation by national decision
makers. As stated previously, such deficiencies can under-
mine the entire healthcare sector and waste scarce
national resources (13, 16).
In Libya, the Libyan Health Law act number 106 of
1973 and its explanatory notes of 1975 state that
registration of medicines within the Libyan Ministry of
Health should precede the availability of any medicine in
the Libyan market. However, the act (and regulations)
only offers a general statement and does not detail the
technical requirements and requisites needed for sound
medicines registration as recommended by the WHO (2).
The limitations of medicine registration in Libya have
been highlighted by Libyan researchers (7, 8) as well as
the WHO (6). In 2003, Faitoori et al. noted the lack of an
active registration process and the negative impact of this
flaw on the quality of medicines in Libya (7). In 2005,
Ekhshaibah also stated that medicine registration is
inactive and is mainly hindered by a lack of indepen-
dence, minimal infrastructure, and the lack of appro-
priately trained personnel (8). The WHO has stated that
medicines registration in Libya not only lacks the
availability of a defined independent body, but also
operates with a limited technical capacity and infrastruc-
ture that is not sufficient for the optimal approval of the
quality, safety, and efficacy of medicines in the Libyan
healthcare system (6, 8, 15). The WHO also stated that
appropriately equipped government quality assurance
laboratories are lacking and quality assurance is mainly
undertaken in some schools of pharmacy with limited
expertise and operating facilities (6).
Although acknowledged as an area that requires
improvement, there is no current available data in relation
to how many products may be substandard in Libya (8),
but media reports have indicated an alarming problem
with medicines quality in Libya (1). In summary, medi-
cines registration in Libya requires review, restructuring,
and the implementation of a revised, thorough system in
line with the WHO guidelines. It is also important to
reinforce the requirement of universal medicines registra-
tion for all subsidized and privately available medicines in
Libya.
Fig. 1. Key activity areas in the pharmaceutical sector.
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Medicines vary in efficacy and price, therefore not every
registered medicine is a candidate for government sub-
sidy. A limited subset of registered medicines needs to be
selected for the purpose of government subsidy (3, 4).
Logically, this subset of medicines should be selected in
reference to predefined criteria that ensure efficient
coverage of the general pharmaceutical needs of the
national population (2, 9). The WHO has created the
Essential Medicines Concept (EMC) as a standardized
framework that aids in appropriate medicines selection
(17, 18).
The Essential Medicines Concept (EMC)
The EMC revolves around the selection of a subset of
government subsidized medicines that are safe, clinically
effective, and also cost effective. These government
subsidized medicines should be available to treat the
commonest national diseases and health conditions. The
WHO has named this subset of medicines as ‘essential
medicines’ (19). Essential medicines are:‘those that satisfy
the priority health care needs of the population. They are
selected with due regard to public health relevance,
evidence on efficacy and safety, and comparative
cost-effectiveness. Essential medicines are intended to be
available within the context of functioning health systems
at all times, in adequate amounts, in the appropriate
dosage forms, with assured quality and adequate informa-
tion, and at a price the individual and the community can
afford. The implementation of the concept of essential
medicines is intended to be flexible and adaptable to many
different situations. Exactly which medicines are regarded
as essential remains ‘‘a national responsibility’’’ (17). The
definition of essential medicines clearly identifies the
public health relevance of selected medicines, evidence
on efficacy and safety, comparative cost effectiveness, and
the availability of essential medicines in the appropriate
dosage forms asthebaseline criteriaof medicines selection
for government subsidy schemes.
The list that encompasses national essential generic
medicines has been named by the WHO as the National
Essential Medicines List (NEML) (17). According to the
WHO, the NEML should be the basis of medicines
selection for public procurement (government subsidy
schemes) as well as other medicines’ use activities in the
public health system (20, 21).
The process of medicines selection for the NEML
should be formalized by allocation of the task of
medicines selection to a defined committee that is
equipped with the appropriate technical skills. Appro-
priate technical skills include: current knowledge of
clinical studies and therapeutics, adverse drug reactions,
national morbidity and mortality shifts, and pharmaco-
economics and cost evaluation studies (9). The process of
medicines selection should also be open and dynamic, i.e.
the NEML should undergo periodical review in order to
keep up with advances in therapy and national morbidity
shifts (5). In addition, a sound national health informa-
tion system is a necessary prerequisite to enable the
compilation and review of a country’s most prevalent
diseases and conditions (6, 22, 23).
The WHO Model List of Essential Medicines
(WMLEM)
Since the actual task of medicines selection for a NEML
is technically complex and requires an array of resources
and skilled professionals that may not be available in
developing countries (3, 5, 9), the WHO has identified a
subset of medicines that are safe, effective, and cost
effective for the world’s most common diseases and
conditions. This subset of medicines is listed in the
WHO Model List of Essential Medicines (WMLEM)
and the list has been regularly updated since 1977.
Essential medicines listed in the WMLEM represent the
minimum number of medicines that are recommended to
be available within any fully functioning healthcare
system and should be the foundation of any NEML
(17, 18, 24).
Medicines selection in Libya
In the past, the National Pharmaceutical and Medical
Equipment Company (NPMEC) was responsible for
medicines selection for public procurement as well as
distribution to public healthcare facilities in Libya in
accordance with Act number 69 of 1972, for regulating
thedrugtrade (7).Historically,medicineswereselectedfor
publicprocurement(fullgovernmentsubsidyofmedicines)
from the national standard list of medicines, commonly
knownastheLibyanPharmaceuticalList(LPL).TheLPL
was originally formulated by the Libyan Ministry of
Health and is a list of all registered medicines in the
Libyan healthcare system. For several decades, the LPL
was employed by the NPMEC for public procurement in
order to cater for the subsidized pharmaceutical needs of
Libyansocietywithsafeandqualitymedicinesthatdidnot
financially overburden healthcare by allowing open pur-
chases of medicines from the international market.
However, the selection of medicines in Libya, as
represented by the LPL, was flawed at multiple levels (7,
8). The LPL was too vast, since it included all registered
medicines in the Libyan healthcare system; therefore,
regular procurement of all medicines listed on the LPL
was impractical and imposed a burden on the Libyan
healthcare budget. As a result, officials allocated with the
task of procuring medicines had to select a limited subset
of medicines for public procurement. However, their
selection method was unsystematic and based on local
estimations of need. This non-systematic approach ulti-
mately affected the reliability and consistency of medicine
supply to national public health facilities. In addition, the
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and unnecessary medicines (8, 15). This was largely the
result of an inefficient medicines registration system that
hindered addition or deletion of any medicines that were
listed on the LPL. It is also important to note that the
actual contents and details of the LPL were not freely
available for scrutiny by Libyan health professionals,
particularly physicians (7).
In 2003, local researchers recommended the implemen-
tation of a NEML in order to rectify the problem of
medicines management in Libya (7). According to local
information (8) and information from the WHO (6), the
National Committee of Drugs was formulated in 2003
and entrusted with the task of reviewing the LPL. Local
information showed that this task was held back by the
lack of national expertise on appropriate medicines
selection (8). In 2005, a draft list was published on the
WHO website.
1 However, this list encompassed several
irrational and superseded medicines. In 2006, the LPL
was cancelled and replaced by a new Libyan national
standard list of medicines  the Libyan Pharmaceutical
List of Essential Medicines (LPLEM). According to the
Department of Pharmacy and Medical Equipment in the
Libyan Ministry of Health, the LPLEM encompassed
only essential medicines (rather than all registered
medicines in the health system) as advocated by the
WHO. The LPLEM continues to be the current Libyan
national standard list for general procurement (full
government subsidy of medicines).
The overview of the history of medicines selection in
Libya indicates that the process of medicines selection for
public procurement purposes in Libya lacks a declared
methodical procedure that follows the WHO guidelines
and that is available for scrutiny by Libyan healthcare
professionals. In addition, review of the Libyan standard
reference list has never been undertaken at regular
temporal intervals since it requires a directive from the
Libyan cabinet (7). Such directives are not automatically
generated, therefore a regular review of the list has been
haphazard. The process of medicines selection in Libya
thus requires reconsideration by national decision makers.
Medicines procurement
The procurement activity involves the task of the actual
purchasing of medicines in an efficient manner. The
interaction between drug manufacturers and the national
healthcare system takes place at this critical interface
(3, 5, 9). Procurement involves a spectrum of duties such
as quantification of national pharmaceutical needs, bulk
purchasing, establishment of bidding contests, technical
analysis of offers, allocation of financial resources,
payments, receipts of purchased medicines, quality assur-
ance checks, and stock management. These activities also
need to be standardized and carried out in a systematic
manner in order to ensure sound and efficient procure-
ment of medicines (9). Sound procurement requires a
robust NEML, reliable data on actual consumption of
medicines in national healthcare facilities, personnel
trained in appropriate procurement practices, and suffi-
cient financial resources in order to appropriately quan-
tify and purchase national pharmaceutical needs (3, 5, 9).
Medicines procurement in Libya
In the Libyan healthcare system, procurement is under-
taken via reference to the national standard reference list,
currently the LPLEM. However, minimal information is
available in relation to the actual procurement process.
According to the available evidence, procurement in the
Libyan health system is not a temporally standardized
process and occurs via annual or biennial tenders
according to random estimation of national needs
(7, 8). Appropriate procurement is also hindered by the
lack of a systematic process of quantification of medi-
cines as well as the lack of properly trained personnel in
relation to the technical details of appropriate procure-
ment techniques and practices (7). Medicines procure-
ment in Libya requires indepth attention as it is not
undertaken in concordance with current WHO guide-
lines.
Medicines distribution
The main function of a national medicines distribution
system is to ensure efficient delivery of purchased
pharmaceuticals to national warehouses and dispensing
outlets. Efficient distribution systems must have storage
facilities  including refrigeration units  that fulfill the
WHO recommendations in order to ensure that medi-
cines are stored and transported in the appropriate
conditions that preserve the therapeutic qualities of
medicines. Security measures should also be in place in
order to minimize the risk of theft and medicines seepage
outside the national public healthcare system. In addi-
tion, it is important to ensure the accurate flow of
inventory information as a critical aspect of medicines
distribution in order to make certain that stocks are
appropriately managed and supplied (2, 3, 9).
Medicine distribution in Libya
According to Faitoori et al., distribution in the Libyan
pharmaceutical sector of the Libyan healthcare system
has endured several limitations that hinder efficient
performance (7). Such limitations include, but are not
limited to, weak transportation systems, obsolete inven-
tory management systems (medicines expire in storage),
lack of coordination between storage and transportation
systems, lack of computerized information systems, and
weak security and monitoring systems that lead to
1Available from: http://www.emro.who.int/emp/Publications_
Details.asp?ID=251.
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Medicines distribution processes in Libya also require
review and reorganization in order to comply with
current the WHO guidelines.
Medicines use
Effective medicines outcomes are ultimately the most
important aspect of medicine use. It is here that patients
experience either the benefits or the detriments of the
pharmaceuticals provided by the national healthcare
system. This activity area is the most difficult to assess
since it involves the interplay of physicians, pharmacists,
patients,andotherswhomayhaveconflictingintereststhat
can compromise medicines use in the national healthcare
system (5, 9). The WHO recognizes inappropriate (irra-
tional) use of medicines as a common practice worldwide
(15). According to the WHO, more than half of all
medicines are prescribed, dispensed, or sold inappropri-
ately, and that only about halfof all patients use medicines
in a correctmanner. The WHO has proposed a framework
on the rational use ofmedicines as an essential component
of the EMC (21). According to the WHO, medicines use
should be formalized, standardized, and governed by
regulatory as well as educational interventions (21). The
problem of irrational medicines use exists in both low
resource as well as high resource countries (15). However,
theproblemismoresignificantindevelopingcountriesdue
to many aggravating contextual factors that hinder the
appropriate (rational) use of medicines (25).
Standardization of medicines use is an important
component of national medicine policies (2) and modern
healthcare delivery; since misuse, overuse or under use of
medicines can impose a silent but serious threat to public
health and, as a result, wastes the limited national
resources (15). A NEML that has been formulated in
concordance with the WHO guidelines is central to the
rational use of medicines as it improves medicines
availability and enhances all educational efforts (for
health professionals as well as patients) on the rational
use of medicines. Liang et al. also recommended ten
approaches that can be utilized by national decision
makers in developing countries to standardize the
medicines use process (20). These approaches include
the implementation of a NEML that is linked to robustly
developed standard treatment guidelines, drug informa-
tion centers that provide health professionals with up-to-
date independent drug information as well as other
training and managerial measures.
It is also important to mention that the problem of
irrational use of medicines requires collaborative efforts
from all stakeholders in the pharmaceutical sector
(physicians, pharmacists, government officials (the Min-
istry of Health), national medical associations, academia,
and others) (26), therefore, measures and initiatives for
the rational use of medicines should be administrated at
the government level.
Medicines use in Libya
The WHO asserts that activities on the rational use of
medicines in Libya need to be assessed and developed (6).
The availability of information on patterns of use of
medicines has been hindered by the general scarceness
of published research in Libya (6, 27). ‘Absence of health
systems research as an integral part of national health
development can be considered as ‘one of the major
constraints that faces health development in Libya’ (6).
We identified one study published in 1988 that
investigated the prescribing patterns in six out-patient
clinics in Tripoli (28). The study found that anti-infective
medicines were prescribed at a high rate (85% of studied
prescriptions). Vitamins (63%), analgesics (61%), anti-
histamines (35%), medicines acting on the gastrointest-
inal tract (19%), and hematinics (11%) were
also commonly prescribed to patients. Another study
published in 2003 identified a potential medication use
problem (over prescribing of antibiotics and pain-killers),
however, this problem was embedded in an availability of
medicines in Libyan public healthcare facilities review
(7). More research examining the current quality
of medicines’ use in Libya is critical and will assist in
improving healthcare in Libya (2, 25).
Also of note, the website of the Libyan Board of
Medical Specialities
2 does not currently include any
educational activities in relation to the rational use of
medicines as advocated by the WHO. In addition, specific
practice guidelines, including therapeutic guidelines on
the appropriate use of medicines are currently lacking at
all levels of the healthcare system (6). Inter professional
collaboration and evidence-based decision making are
essential components for activities on the rational use of
medicines and modern healthcare delivery (21, 26). The
Libyan healthcare system needs to encourage profes-
sional collaboration and evidence-based decision making
(6). Overcoming such constraints is the first step toward
the rational and effective use of medicines in Libya.
Transparency in medicines management
In order to ensure sound performance of the pharma-
ceutical sector, most activities in medicines management
need to operate in a transparent manner that allows
scrutiny by national healthcare professionals and other
stakeholders (5, 9). For instance, national medicines
regulatory authorities (registration systems) need to be
formalized and applied in an open and reliable manner
that complies with the WHO guidelines. There is no place
for personal judgment or inappropriate practices that
2Available from: http://www.lbmlibya.org/index.php.
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national healthcare system (2, 3, 5, 9).
Transparency is also an indispensable component of
the selection activity for medicines management. Infor-
mation in relation to the committee entrusted with the
task of selecting medicines for the NEML should be
publicly disclosed (on a website or similar channels) in
order to ensure accountability and avoid inappropriate
practices that endanger the quality and availability of
medicines in the national healthcare system (5, 9, 17).
It is also important to mention that the stability of the
pharmaceutical sector is a key component that secures
long-term planning and sustainability of pharmaceutical
services in any health system (2, 3). Stability has been a
majorissuethathasundermineddevelopment,review,and
improvement of the Libyan pharmaceutical sector (7, 8).
Conclusion
The sound and systematic management of the pharma-
ceutical sector is a critical requisite for the appropriate
supply and use of medicines in the national healthcare
system. In order to improve the pharmaceutical sector,
the processes involved in medicines management need to
be clearly defined in the Libyan national healthcare
system. This will require extensive resources, thoughtful
planning, and technical expertise. In addition, scarceness
of research evidence and review in relation to all activities
undertaken within the pharmaceutical sector is an area
that can and needs to be addressed by appropriate
research.
Recommendations
The Libyan management of the pharmaceutical sector
does not measure up to the standards recommended by
the WHO. A key reason for the suboptimal performance
of the pharmaceutical sector in Libya is the lack of
stability, appropriate infrastructure, and well-trained
personnel. Urgent attention and support from national
decision makers is required for the optimal performance
of the sector, which is critical to the healthcare of Libyan
society.
We therefore recommend:
1) Effective adoption of the WHO guidelines in rela-
tion to all five critical activities in the pharmaceu-
tical sector.
2) Encouraging research projects that will assess and,
ultimately improve, the Libyan pharmaceutical and
healthcare system.
3) Adoption of transparent measures in all five critical
activities in order to enhance performance and
accountability.
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